| Primary |
| Gout |
34.9% |
| Hyperuricaemia |
23.3% |
| Hypertension |
11.6% |
| Tumour Lysis Syndrome |
4.7% |
| Type 2 Diabetes Mellitus |
4.7% |
| Arthralgia |
2.3% |
| Cardiovascular Event Prophylaxis |
2.3% |
| Depression |
2.3% |
| Dyslipidaemia |
2.3% |
| Hepatic Enzyme Increased |
2.3% |
| Hyperlipidaemia |
2.3% |
| Insomnia |
2.3% |
| Product Used For Unknown Indication |
2.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.3% |
|
| Renal Failure Acute |
12.0% |
| Urticaria |
12.0% |
| Hyperkalaemia |
8.0% |
| Dizziness |
4.0% |
| Drug Effect Decreased |
4.0% |
| Gastric Ulcer Haemorrhage |
4.0% |
| Heart Rate Increased |
4.0% |
| Hepatic Enzyme Increased |
4.0% |
| Hepatic Failure |
4.0% |
| Leukopenia |
4.0% |
| No Adverse Event |
4.0% |
| Oedema Peripheral |
4.0% |
| Peritonitis |
4.0% |
| Pruritus |
4.0% |
| Rash |
4.0% |
| Rash Generalised |
4.0% |
| Rectal Haemorrhage |
4.0% |
| Renal Impairment |
4.0% |
| Restlessness |
4.0% |
| Rhabdomyolysis |
4.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
21.0% |
| Hypertension |
16.0% |
| Gout |
12.2% |
| Product Used For Unknown Indication |
8.7% |
| Hyperuricaemia |
7.3% |
| Hypercholesterolaemia |
4.1% |
| Prophylaxis |
4.1% |
| Rheumatoid Arthritis |
2.9% |
| Atrial Fibrillation |
2.3% |
| Gastrooesophageal Reflux Disease |
2.3% |
| Hypothyroidism |
2.3% |
| Immunosuppression |
2.3% |
| Diabetes Mellitus |
2.0% |
| Hyperlipidaemia |
2.0% |
| Pain |
2.0% |
| Asthma |
1.7% |
| Medical Diet |
1.7% |
| Renal Transplant |
1.7% |
| Angina Pectoris |
1.5% |
| Gastric Ulcer |
1.5% |
|
| Renal Failure Acute |
13.0% |
| Renal Failure |
10.9% |
| Heparin-induced Thrombocytopenia |
8.7% |
| Leukocytoclastic Vasculitis |
6.5% |
| Cerebrovascular Accident |
4.3% |
| Gastrointestinal Polyp Haemorrhage |
4.3% |
| Hepatic Failure |
4.3% |
| Hepatitis Acute |
4.3% |
| Intestinal Obstruction |
4.3% |
| Pancytopenia |
4.3% |
| Presyncope |
4.3% |
| Pruritus |
4.3% |
| Rash |
4.3% |
| Respiratory Failure |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Vomiting |
4.3% |
| Acute Myocardial Infarction |
2.2% |
| Blood Lactate Dehydrogenase Increased |
2.2% |
| Cardiac Failure Acute |
2.2% |
| Chest Pain |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.9% |
| Hypertension |
8.3% |
| Rheumatoid Arthritis |
6.2% |
| Gout |
6.0% |
| Hyperuricaemia |
4.4% |
| Insomnia |
4.4% |
| Pain |
4.3% |
| Prophylaxis |
3.5% |
| Constipation |
3.4% |
| Diabetes Mellitus |
3.4% |
| Renal Transplant |
3.4% |
| Atrial Fibrillation |
2.8% |
| Acute Myeloid Leukaemia |
2.7% |
| Premedication |
2.5% |
| Cardiac Failure |
2.1% |
| Infection Prophylaxis |
1.8% |
| Osteoporosis |
1.6% |
| Anxiety |
1.4% |
| Cancer Pain |
1.4% |
| Cardiac Failure Chronic |
1.4% |
|
| Renal Failure Acute |
8.8% |
| Death |
7.0% |
| Rhabdomyolysis |
7.0% |
| Urinary Tract Infection |
7.0% |
| Vomiting |
7.0% |
| Brain Abscess |
5.3% |
| Fall |
5.3% |
| Rash |
5.3% |
| Rhinorrhoea |
5.3% |
| Stevens-johnson Syndrome |
5.3% |
| Upper Limb Fracture |
5.3% |
| Atrial Flutter |
3.5% |
| Gastric Ulcer |
3.5% |
| Generalised Oedema |
3.5% |
| Hemiparesis |
3.5% |
| Hypoglycaemia |
3.5% |
| Infusion Related Reaction |
3.5% |
| Interstitial Lung Disease |
3.5% |
| Lacunar Infarction |
3.5% |
| Overdose |
3.5% |
|
| Interacting |
| Gout |
38.5% |
| Renal Transplant |
38.5% |
| Immunosuppression |
23.1% |
|
| Drug Interaction |
42.9% |
| Blood Bilirubin Increased |
14.3% |
| Influenza |
14.3% |
| International Normalised Ratio Increased |
14.3% |
| Vomiting |
14.3% |
|
